Summit Therapeutics
SMMT
8 hedge funds and large institutions have $33.2M invested in Summit Therapeutics in 2015 Q1 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
2.74% more ownership
Funds ownership: 0% → 2.74% (+2.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lansdowne Partners (UK)
London,
United Kingdom
|
+$10.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.5M |
| 3 |
Axa
Paris,
France
|
+$3.32M |
| 4 |
First Eagle Investment Management
New York
|
+$1.98M |
| 5 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.98M |
Top Sellers
SMMT Hedge Fund Activity: Q1 2015 in Review
8 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2015, worth a combined $33.2M.
Buyers outnumbered sellers: 8 funds opened new SMMT positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Lansdowne Partners (UK), opening a new position worth an estimated $10.5M.
- 8 institutional investors held Summit Therapeutics (SMMT) as of Q1 2015, up from 0 in Q4 2014.
- Funds reported $33.2M of Summit Therapeutics stock for Q1 2015.
- 8 funds opened new Summit Therapeutics positions in Q1 2015 and 0 closed out, a net change of +8 holders.
- The largest Summit Therapeutics buyer in Q1 2015 was Lansdowne Partners (UK), an estimated $10.5M added.
Based on aggregated 13F filings for Q1 2015.